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http://dxObjectives: Introduction of a new procedure has a typical learning curve with the ‘‘learning phase’’ at the begin-
ning, characterized by an increasedmortality or complication rate.Wedeveloped our institutional structured train-
ing program for transcatheter aortic valve implantation (TAVI) with the aim of eliminating these negative effects.
Methods: The program regulated the introduction of TAVI and building and training of the team. It combines
cumulative knowledge from the field with the institutional and individual background experience. It includes
stepwise acquisition of the tools necessary for the preoperative strategic planning, perioperative team commu-
nication, technical aspects of the procedure, and postoperative management. The program establishes a basis for
interaction and feedback between the members of the team (‘‘teach and learn’’; ‘‘be proctor and proctored’’).
Results: The program consists of 4 main parts: general principles, team building, team education and training,
and the institutional clinical and procedural policies. The program possesses several control mechanisms, eg,
occasional external proctoring. Additionally, a chain of steps spontaneously generates further procedural im-
provements and optimizes the overall outcome. The program has also had a global positive effect on the local
institutional environment, awaking awareness of existing latent conditions and active failures, identifying them
and inducing their correction, which has led to general clinical improvement.
Conclusions: A structured educational training program enables implementation of a new procedure (TAVI) into
clinical practicewithout increasedmorbidity andmortality rate during the learning curve. Theprogrammayalso be
used as a basis for any new device introduction into clinical practice. (J Thorac Cardiovasc Surg 2013;145:919-25)Implantation of a biologic prosthetic valve in the aortic
valve position by a catheter, called transcatheter aortic
valve implantation (TAVI), has its experimental roots in
1965 when Davies1 put a valve mounted on a catheter
into a descending thoracic aorta. The basic experimental
work in this field done by Andersen and colleagues2 and
published in 1992 enabled later clinical application of
TAVI beginning in 2002.3-5 This long-lasting pioneering
path of different individuals and institutions resulted in
enormous cumulative knowledge that has led to fast intro-
duction of TAVI in a number of centers worldwide. TAVI
is currently a broadly established treatment method with
different types of valves used (self-expandable, balloon ex-
pandable) and the different possible ways of implantation
(transfemoral, transapical, transaxillary, transaortic).eutsches Herzzentrum Berlin, Berlin, Germany.
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The Journal of Thoracic and CaTransapical TAVI is a more difficult technique than trans-
femoral implantation and requires a longer learning curve.6 It
is a ‘‘procedure of 1001 details,’’ a series of small sequences
that need to be performed precisely, in perfect order, andwith
perfect timing and excellent coordination between the mem-
bers of the team.7 It combines both precise surgical technique
and interventional skills, and therefore departs from standard
surgical policies and requires new ways of thinking.6 Failure
in a single sequence may produce a disastrous situation with
dangerous and life-threatening complications.7
The clinical application of TAVI program was started at
Deutsches HerzzentrumBerlin in April 2008 and introduced
according to our intensive and structured program for the
building, education, and training of the team. We report
our institutional structured training program for TAVI.6-24
MATERIALS AND METHODS
The institutional training program regulates the introduction of the TAVI
procedure at the Deutsches Herzzentrum Berlin (Berlin, Germany). It was
developed by a senior team member (M.P.) commissioned to introduce
and establish TAVI at Deutsches HerzzentrumBerlin. The program consists
of 4main parts: (1) general principles, (2) team building, (3) team education
and training, and (4) the institutional clinical and procedural policies.
GENERAL PRINCIPLES
1. TAVI should be validated as a safe and reliable proce-
dure.rdiovascular Surgery c Volume 145, Number 4 919
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
LVEF ¼ left ventricular ejection fraction
LVOT ¼ left ventricular outflow tract
MSCT ¼ multislice computed tomography
TAVI ¼ transcatheter aortic valve implantation
TEE ¼ transesophageal echocardiography
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match the results of the already established method
(conventional aortic valve replacement) applied in the
same patient population at Deutsches Herzzentrum
Berlin.
3. The technical provisions in terms of a special hybrid
operating room that combines a catheter laboratory
should provide the preconditions necessary to perform
surgery and sterile valve preparation before implanta-
tion, anesthesiologic equipment, appropriate lighting,
and the heart-lung machine.
4. The TAVI team should be built, educated, and trained
on the basis of contemporary knowledge and general
institutional experience.
5. The TAVI team should be trained to perform all types of
TAVI, including the management of the possible proce-
dural complications.
6. Before every implantation, the team should analyze the
patient’s characteristics, analyze the possible course of
the procedure and possible complications, and identify
how to act in the particular situation.
7. After every implantation, the team should analyze the
course of the procedure and complications and identify
possible weak points of the procedure and possible pro-
cedural improvements.
8. Institutional clinical and procedural polices should be
established and regularly updated.
9. The whole process of the TAVI procedure should be
uniform and should comply with the established insti-
tutional practice.
10. A separate TAVI data bank should be established.
11. Treatment of patients undergoing TAVI should be orga-
nized as a chain from the beginning to the end of hos-
pitalization and in the outpatient follow-up.
12. The TAVI program should be organized to be able to
provide the institutional service 24 hours per day.
13. The TAVI program, including the technical precondi-
tions and safety of the new procedure, the technical
part of the procedure and the clinical results, should
be continuously monitored, documented, analyzed,
and improved.
14. The above principles should be complied with; other-
wise the program should be redefined.920 The Journal of Thoracic and Cardiovascular SurgBUILDING OF THE TEAM
The institutional team consists of 2 parts: the core team
and the virtual team. The core team comprises 2 anesthesi-
ologists with expertise in transesophageal echocardiogra-
phy (TEE), 5 surgeons of 4 different surgical generations,
and 2 experienced cardiologists. The virtual team consists
of approximately 50 persons involved in the chain of treat-
ment of patients undergoing TAVI from the beginning to the
end of hospitalization and in the outpatient follow-up. Rep-
resentatives of the valve manufacturing companies are con-
sidered to be members of the virtual team. The persons in
the virtual team should not necessarily be known to be
involved in the virtual team.EDUCATION AND TRAINING
1. Review of the contemporary cumulative knowledge
from the field.
2. Theoretic procedural preparation.
3. Training on a computer simulator.
4. Training by dry runs.
5. Visits to teaching centers with live procedural case
demonstrations.
6. Repeated proctoring by external experts.
7. Internal proctoring by the members of the team them-
selves.
8. Visits to other colleagues and exchange of experience.
9. Attendance at scientific meetings with presentation of
the institution’s own experience.
10. Publication of results and experience.
11. Continuous review of the new literature.
12. Live broadcasting of the teaching cases.
13. Helping other colleagues to establish their own pro-
grams (proctors for the manufacturers of the valves).
14. Cooperation with other cardiologists from the
region.
15. Fellowships for guest doctors.
16. Cooperation with industry.
There were 2 modes of proctoring: external and inter-
nal. The external proctoring was performed by experts
in the field who were from different centers. External
proctoring was applied for the first cases by the pioneer-
ing experts depending on the type of TAVI procedure.
Later on, this was continued by occasional and repeated
visits from other experts with the aim to exchange expe-
rience, to improve the details of the procedure, and to
identify possible invisible or systemic errors that might
be inherent in the TAVI process. The internal proctoring
was managed as a self-appraisal relationship with regard
to surgical experience between the members of the team
where opinions were exchanged in an open discussion
during the evaluation of the TAVI processes. Principally,
if there were 2 or more similar alternatives, the suggestionery c April 2013
TABLE 1. Checklist during transapical transcatheter aortic valve
implantation
1. Puncture of ventricular apex
2. Passage of guidewire through valve
3. Small-bore introducer (14F) through valve
4. Exchange of standard guidewire with stiff guidewire
5. Passage of valvuloplasty balloon through the valve
6. Preparation of the external pacemaker
7. Disconnection of the ventilation tube from the ventilator
8. Activation of the pacemaker at 160 beats/min
9. Output is reduced
10. Balloon inflation
11. Contrast injection (before full inflation of the valvuloplasty balloon)
12. Balloon deflation
13. Discontinuation of the external pacing
14. Reconnection of the ventilation tube to the ventilator
15. Removal of small-bore introducer
16. Insertion of large-bore (24F or 26F) introducer
17. Valve forwarding through introducer
18. Deaeration of the introducer system
19. Removal of valve pusher
20. Contrast injection (for initial selection of adequate valve position)
21. Preparation of the external pacemaker
22. Disconnection of the ventilation tube from the ventilator
23. Activation of the pacemaker at 160 beats/min
24. Output is reduced
25. Contrast injection (to confirm position)
26. Balloon inflation
27. Contrast injection (for fine correction of valve position)
28. Balloon complete inflation (and count ‘‘21-22-23’’)
29. Balloon deflation
30. Discontinuation of the external pacing
31. Reconnection of the ventilation tube to the ventilator
32. Balloon retraction within introducer
33. Note the recovery (or absence) of the heart function
34. Retract the introducer, balloon-catheter, and the super-stiff guidewire
35. Close the apex
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team. This established a basis for interaction and feedback
between the members of the team (‘‘teach and learn’’).
Each member had full freedom in decision-making and
in performing the procedure in accordance with the insti-
tutional policies for TAVI established by the team itself.
The internal proctoring was basically performed by the
most experienced surgeon/cardiologist (‘‘senior proc-
tors’’) and then gradually taken over by other members
of the team (‘‘younger proctors’’), according to their sur-
gical experience, who were taught to allow interactive
proctoring (‘‘be proctor and proctored’’). During the ini-
tial internal phase, the senior proctors performed all pro-
cedures if complications were expected because of
patients’ clinical condition (eg, poor left ventricular ejec-
tion fraction [LVEF], cardiogenic shock, age 90 years,
special situations).
The internal proctoring was divided into 4 segments and
aimed at achieving complete understanding and indepen-
dence in the various phases of the TAVI process.
Segment 1 consisted of proctoring of preoperative patient
evaluation and determination of the indication in general.
Segment 2 was performed in the hybrid operating room
immediately before the procedure. It included proctoring
the analysis of the patient’s preprocedural evaluation, multi-
slice computed tomography (MSCT) and echocardio-
graphic annulus assessment, valve size determination, and
analysis of possible procedural problems. In this phase,
the ‘‘trainee’’ should acquire the knowledge to adequately
measure the size of the aortic annulus mainly by means of
TEE and be able to determine it by him/herself. Appropriate
valve selection, on the basis of the global aortic anatomy
and the patient’s characteristics, was the most important
final goal of segment 2.
Segment 3 consisted of 2 different parts: proctoring of
valve preparation and crimping followed by proctoring of
the technical parts of the procedure itself.
The first part was propaedeutic to the second part, and
each member of the team had to achieve full knowledge
of the disposable materials and full independence in valve
preparation before starting with the technical parts of the
procedure itself.
The second part of segment 3 included an early (‘‘assis-
tant’’) phase and a late (‘‘first operator’’) phase for the
trainee. During the ‘‘assistant phase,’’ the trainee would be-
come familiar with the various steps of the procedure and
focus on some simple but focal tasks, such as maintaining
the transapical introducer and stiff guidewire position dur-
ing manipulation and catheter insertion/removal, air purg-
ing, and correct timing for contrast agent injection during
the controlled valve release. Coordination with the operator
to minimize left ventricular apical bleeding during insertion
and removal of the large-bore introducers was also prac-
ticed during this phase. In preparation to the ‘‘operatorThe Journal of Thoracic and Caphase’’ of segment 3, the trainee was also required to learn
by heart and recite with the correct emphasis the standard-
ized commands given during the implantation phases of the
procedure by the operator (Tables 1 and 2). Commands need
to be clearly stated to alert the other team members to the
various phases of aortic valvuloplasty and prosthesis
implantation.
The ‘‘operator phase’’ of segment 3 was performed in
5 periods (A-E) and includes active and passive proctor-
ing. In period A, the internal proctor is scrubbed and is in
the team performing the procedure, either on the same
side as the operator or on the opposite side. During this
phase, the trainee will progressively acquire the neces-
sary knowledge to perform independently the various
phases of the procedure. Initially, emphasis will be given
to the identification of the correct site to perform the tho-
racotomy to minimize the trauma and optimize the access
to the ventricular apex, appropriate selection of the leftrdiovascular Surgery c Volume 145, Number 4 921
TABLE 2. Command list* during transcatheter aortic valve
implantation (corresponding to Table 1)
1. Apical puncture!
2. Guidewire is coming!
3. 14F introducer is coming!
4. (no command) (exchange of standard guidewire with stiff guidewire)
5. Valvuloplasty balloon is coming!
6. Pacemaker ready?
7. Disconnect the tube!









15. 14F introducer is coming out!
16. 26F (or 24F) introducer is coming!
17. Valve is coming! (alert to valve introduction)
18. No command (deaeration of the introducer system)
19. Pusher backward!




23. Pacemaker on! 160! (if necessary, additional command: pacemaker
180!)
24. No output!
25. Angio! (Contrast injection to confirm position)
26. Balloon inflation!
27. Angio! (Contrast injection for fine correction of valve position)
28. No command (after complete balloon inflation count loudly: ‘‘21-22-
23’’)
29. No command (balloon deflation)
30. Pacemaker off!
31. Reconnect tube!
32. No command (balloon retraction within introducer)
33. Is recovering! (note the recovery [or absence] of the heart function)
34. No command (pull back and retract the introducer, balloon-catheter,
and super-stiff guidewire)
35. No command (information if there should be problems with closure of
the apex)
*Commands should be learned by heart during the ‘‘assistant’’ phase of the training
and given only by the operator, loudly and clearly. They serve to guide and coordinate
the entire TAVI team during the various phases of the procedure.
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tricular purse-strings. In a second stage, the trainee will
familiarize him- or herself with transapical puncture,
guidewires and introducer passage, and valve positioning
and release. In period B, once the trainee has acquired
the necessary skills to perform the various steps, the in-
ternal proctor is in the hybrid operating room and is
scrubbed but does not assist in the procedure. In period
C, the internal proctor is in the hybrid operating room
but is not scrubbed and not active at the operating field.922 The Journal of Thoracic and Cardiovascular SurgIn period D, the internal proctor is in the operation tract
but not in the hybrid operating room. The last period of
segment 3 is period E, the ‘‘no-proctoring’’ phase where
the trainee has fully acquired and developed all the nec-
essary skills to perform the various stages of the proce-
dure independently.
Segment 4 consists of proctoring of the evaluation of the
procedure and the postprocedural patient management.INSTITUTIONAL CLINICAL AND PROCEDURAL
POLICIES
The institutional policies contain the guidelines on how
to act in particular situations with regard to patient selec-
tion, procedural steps, and complications.6-24 They are
now updated as of December 2011.
1. Indications: The patients can be evaluated and accepted
for TAVI according to the contemporary accepted crite-
ria after comparison with the present institutional prac-
tice. The patients who do not fulfill the criteria may be
accepted for TAVI for technical surgical reasons
(eg, porcelain aorta) or because of a very high risk for
conventional operation due to factors not covered by
the risk scores (eg, liver cirrhosis, malignancy, or in
special situations such as in patients with assist de-
vices). The reason or reasons must be widely accept-
able and clearly formulated and documented.
2. ‘‘No exclusion’’ policy: All very high-risk patients, in-
cluding those with poor LVEF (10%-20%) or cardio-
genic shock or those requiring a rescue procedure,
should be considered for TAVI (except thosewith endo-
carditis or too large annuli). No patient should be re-
fused because of comorbidities.
3. Contraindications: The absolute contraindications for
TAVI are active or recent endocarditis or an annulus
size that exceeds the recommendations of the valve
manufacturers.
4. Assessment of the device landing zone (left ventricular
outflow tract [LVOT], annulus, cusps, sinuses of
Valsalva, proximal aorta): The annulus is assessed pre-
operatively using transthoracic echocardiography (par-
asternal long-axis view) and MSCT (coronal and
sagittal views), and immediately before TAVI by TEE
(mid-esophageal short and long-axis view; [for the
measurement of the annulus diameter: long-axis view
during the maximal diameter of LVOT in midsystole]).
The reference level is set immediately below the inser-
tion of the cusps (‘‘subannularly’’). In the hybrid oper-
ating room, immediately before TAVI, the diameter of
the annulus is measured first by our TAVI anesthesiol-
ogist(s) with expertise in TEE and then by the sur-
geon(s) and the cardiologist designated for the
particular procedure, while the numeric values are hid-
den (‘‘blinded fashion’’). Next, the results are revealedery c April 2013
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general, the transthoracic echocardiography result is
used only as an orientational value for screening if
the annulus is too large for the use of the contemporary
transcatheter valves.
In particular, the followingmeasurements are performed
(TEE or MSCT): diameters of the LVOT, annulus, and
aorta (at the levels of the sinuses of Valsalva, sinotubular
junction, and mid-ascending aorta), distances between
the coronary artery ostia and the aortic annulus, dis-
tances between the commissures themselves, distances
between each commissure and the aortic wall of the op-
posite sinus of Valsalva. The measurements are per-
formed in conjunction with the evaluation of the
morphology of the heart and aorta, determination of
the projection of the left ventricular apex to the anterior
chestwall, and identification of the shapes of the annulus
(‘‘round’’vs ‘‘oval’’) and proximal aorta (whether the si-
nuses of Valsalva are pronounced or not in comparison
with the mid-portion of the proximal aorta; ‘‘male-
shaped’’ vs ‘‘female-shaped’’). Specific pathologies
influencing the valve-size selection, the procedure and
valve positioning (eg, localized calcified masses, open
or fused commissures), and amount of calcification in
the neighborhood of the commissures are identified.
The number of open or fused commissures is counted
(0 to 3), and the amount of calcification in the device
landing zone is assessed semiquantitatively by visual es-
timation (grade 0 to þþþ).
5. Selection of the valve size: Principally, the size of the
valve used is determined according to the diameter of
the native aortic valve annulus measured by intraoper-
ative TEE (‘‘reference value’’). In general, a 2-mm
oversized valve is used; the 23-mm Edwards Sapien
prostheses (Edwards Lifesciences, Irvine, Calif) are
applied for the aortic annuli with a diameter of less
than 21 mm, and the 26-mm Edwards Sapien prosthe-
ses are applied for annuli with a diameter of 21 to 24
mm. For annuli greater than 24 mm and 27 mm or
less, a 29-mm Edwards Sapien XT valve (balloon ex-
pandable) is used. For the larger annuli (>27 mm and
29 mm), a 31-mm CoreValve (CoreValve Revalving
System; Medtronic Inc, Minneapolis, Minn) (transfe-
moral or transaxillary approach) should be applied or
conventional aortic valve replacement reconsidered
(with cardioplegic arrest if an aortic crossclamp time
of 20 minutes is predicted to be possible, otherwise
on the beating heart using retrograde heart perfusion
through the coronary sinus). (Before a 29-mm Edwards
Sapien XT prosthesis was available, for the annuli
between 24 and 27 mm, we used self-expandable
29-mm CoreValve prostheses [transfemoral or transax-
illary approach].)The Journal of Thoracic and CaIn borderline cases, when measurements ranged around
21 mm (24 mm, respectively), MSCT influenced the
valve size selection. In this case, the decision on valve
sizewasmadeon an individual basis, taking into account
all additional factors, such as the distances from the an-
nulus to the coronary artery ostia, the shape of the annu-
lus (oval vs circular), the amount of material in the
leaflets, the aortic diameters at the level of the sinuses
of Valsalva, the sinotubular junction and ascending
aorta, and the amount of calcification in the LVOT, ante-
rior mitral leaflet, commissures, and aortic valve leaflets
themselves. In borderline cases, the factors that suggest
a smaller valve (and viceversa for a larger prosthesis) are
narrow aortic root with nonpronounced sinuses of Val-
salva (‘‘male-shaped’’ aorta), round shape of the aortic
valve annulus, pronounced or severe calcification of
the device landing zone, fused commissures (with 0-1
open commissure), short (<8 mm) distance between
the annulus and the coronary artery ostia, female gender
of the patient, and body surface area less than 1.8 m2.
6. Use of femoro-femoral cardiopulmonary bypass
(CPB): Elective normothermic femoro-femoral CPB
should be considered in patients with low LVEF
(10%-20%), cardiogenic shock or rescue procedure,
and significantly enlarged right ventricle with poor
right ventricular ejection fraction and severe pulmo-
nary hypertension. CPB (femoro-femoral normother-
mic CPB) is used to stabilize the patients’ condition,
to achieve hemodynamic stability during TAVI, and
to prevent possible manual cardiopulmonary resuscita-
tion if ventricular fibrillation should occur during rapid
pacing for balloon valvuloplasty and during valve de-
ployment. In patients with cardiogenic shock, CPB is
used for additional myocardial recovery of the un-
loaded heart after the new transcatheter valve is
deployed.
7. Prophylactic use of intra-aortic balloon pump: An
intra-aortic balloon pump should be considered in pa-
tients with poor LVEF (10%-20%) and in patients in
cardiogenic shock.
8. Valve deployment: Precise deployment of the new
valve in the desired position should be performed by
slow and gradual inflation of the balloon under visual-
ization of the aortic root structures by simultaneous an-
giography through a pigtail catheter placed in the
proximal ascending aorta above the new valve.
9. Simultaneous treatment of combined coronary artery
disease: Simultaneous elective percutaneous coronary
intervention, or coronary artery bypass grafting if per-
cutaneous coronary intervention is not possible, is con-
sidered in patients with concomitant coronary artery
disease. Only the most relevant coronary artery stenosis
is treated.rdiovascular Surgery c Volume 145, Number 4 923
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valve prosthesis: This concept may be considered in
high-riskpatients as a therapeutic or a palliative approach.
11. Combined atrioventricular valve pathology: Concomi-
tant significant functional atrioventricular valve pathol-
ogy is not treated in combination with TAVI, but later
on by conventional surgery, if necessary. The exception
is tricuspid valve regurgitation of grade IV.
12. Post-implant paravalvular leakage or transvalvular re-
gurgitation: Aortic regurgitation after valve implantation
of grade 1 to 2 (or greater than grade 2) should be treated
by additional balloon dilation of the valve and, if neces-
sary, by implantation of a second valve. In the case of
grade 2 or greater, if it is not correctable, conventional
surgical aortic valve replacement should be considered.
13. Intraprocedural bleeding of unknown origin: Any arte-
rial bleedingwith no identifiable cause should be consid-
ered as suspected annulus rupture, and therefore
immediate institution of CPB and a median sternotomy
should be performed to treat it, even in patients who
are considered formally ‘‘inoperable’’ or ‘‘not suitable
for conventional surgery.’’ Standard aortic valve replace-
ment should be performed, and in the case ofmyocardial
rupture, the LVOT should be reconstructed with an over-
sized pericardial patch. No attempts should be made to
close the rupture of the left ventricle from the outside.
14. Slow myocardial recovery: Patients with poor left ven-
tricular function (LVEF 10%-20%), cardiogenic shock,
or an enlarged right ventricle and pulmonary hyperten-
sion are prone to the intraprocedural complications
(mostly slow recovery of themyocardial function imme-
diately after balloon dilatation of the valve or valve de-
ployment). In this situation, repeatedly administer
additional increased doses of catecholamine (medica-
mentous reanimation) through the central venous cathe-
ter or even give them directly into the aortic root via
pigtail catheter. Consider use of CPB (femoro-femoral).
Consider and exclude (by TEE ¼ short axis view, angi-
ography) iatrogenic obstruction of the coronary artery
ostia or rupture of the aortic root structures. Consider
possible coronary artery (micro)embolization.
15. Special situations: TAVI can be considered but very
cautiously accepted in patients with bicuspid aortic
valve, previous mitral valve replacement or homograft
implantation, and with left ventricular assist devices
who have pure aortic valve insufficiency.
16. TAVI combined with conventional surgery: TAVI can
be combined with conventional heart surgery for com-
plex heart pathology.CONCLUSIONS
Our institutional structured educational and training pro-
gram combines cumulative knowledge from the field with924 The Journal of Thoracic and Cardiovascular Surgthe institutional and individual background experience. It
is applied consecutively as an interactive self-proctoring
of the team during the later period (‘‘be proctor and proc-
tored’’). The aim of the program is to implement TAVI
safely and efficiently into clinical practicewith the intention
not to increase the morbidity and mortality rate during the
learning curve.
The program possesses several control mechanisms, for
example, occasional external proctoring. In addition, a chain
of steps spontaneously generates further procedural im-
provements and optimizes the overall outcome. For exam-
ple, one of the main steps of the program is the obligation
to publish our own results.6-24 This requires a review of
the contemporary literature (thus increasing the individual
and the team knowledge and giving new ideas), includes
self-evaluation of the results (thus enabling additional iden-
tification of the failures and increasing awareness of them),
forces us to make comparison between our own and other
centers (additionally increasing awareness of failures,
need for self-criticism, and desire for improvements), and
generates positive competition between the members of
the team themselves, enhancing their self-esteem (and
thus stimulating prospective publications). It should also
be mentioned that the structured program has had a global
positive effect on the local institutional environment, awak-
ing awareness of existing latent conditions and active fail-
ures,25 identifying them, and inducing their correction,
which has led to general clinical improvement. The pro-
gram also may be used as a basis for any new device intro-
duction into clinical practice.
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